kabutan

Alfresa Holdings Corporation(2784) Summary

2784
TSE Prime
Alfresa Holdings Corporation
2,436.0
JPY
+22.0
(+0.91%)
Dec 12, 3:30 pm JST
15.63
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
12.3
PBR
0.91
Yield
2.79%
Margin Trading Ratio
0.65
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
2,444.5 JPY 15.72 USD
Previous Close Dec 11
2,414.0 JPY 15.46 USD
High Dec 12, 9:00 am
2,444.5 JPY 15.72 USD
Low Dec 12, 12:46 pm
2,414.0 JPY 15.50 USD
Volume
349,500
Trading Value
0.85B JPY 5.46M USD
VWAP
2433.61 JPY 15.62 USD
Minimum Trading Value
243,600 JPY 1,563 USD
Market Cap
0.47T JPY 3.01B USD
Number of Trades
1,010
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
1,308
1-Year High May 15, 2025
4,934
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 36,700 24,100 0.66
Nov 28, 2025 38,200 36,900 0.97
Nov 21, 2025 40,100 32,300 0.81
Nov 14, 2025 52,300 37,900 0.72
Nov 7, 2025 49,500 37,000 0.75
Company Profile
Alfresa Holdings Corporation is Japan's largest pharmaceutical wholesaler. The company was formed through the merger of Fukujin and Azwell. It also engages in pharmaceutical contract manufacturing and medical equipment sales.
Sector
Wholesale Trade
Alfresa Holdings Corporation operates in pharmaceutical wholesale, self-medication wholesale, pharmaceutical manufacturing, and healthcare-related businesses. In its core medical pharmaceutical wholesale business, the company operates nationwide, centered around Alfresa. The self-medication wholesale business handles over-the-counter drugs and health foods. In the pharmaceutical manufacturing business, Alfresa Pharma Corporation manufactures and sells pharmaceuticals and medical diagnostic reagents. The healthcare-related business operates a chain of dispensing pharmacies. As a holding company, Alfresa Holdings Corporation formulates group-wide management policies and business plans, aiming to effectively utilize management resources and continuously enhance corporate value.